Description
A reversible, cell-permeable PLK inhibitor; selectively inhibits Plk1 and Plk3 (IC50s = 2.2 and 9.1 nM, respectively) over more than 30 other kinases in a cell-free assay; inhibits Plk1 activity in vitro in HeLa cells using a chimeric Plk1 reporter assay (IC50 = 0.14 μM); inhibits growth in nine cancer cell lines in a panel (IC50s = 0.11-0.7 μM) but not of PC3 human prostate cancer cells (IC50 = 6.82 μM) or non-cancerous human diploid fibroblasts (HDFs; IC50 = 6.14 µM); inhibits growth of MES-SA human uterine sarcoma cells, as well as of the drug-resistant, P-glycoprotein-expressing MES-SA/Dx5 subline (IC50s = 0.21 and 0.21 μM, respectively); inhibits the growth of patient-derived leukemia cells (IC50s = 2/M cell cycle arrest and apoptosis of H460 human lung and PALL-2 and MOLM13 human leukemia cancer cells in a concentration-dependent manner
Formal name: 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]-2-thiophenecarboxamide
Synonyms:
Molecular weight: 477.5
CAS: 660868-91-7
Purity: ≥98%
Formulation: A crystalline solid